Industry News
Biotechnology Industry News
After HHS abruptly canceled about…
After HHS abruptly canceled about $500 million in funding for mRNA vaccine development, one senior agency leader has decided to call it quits. Alastair Thomson is resigning as chief data officer at the Advanced Research
Using its hub-and-spoke business…
Using its hub-and-spoke business model, PureTech is launching a new subsidiary, Celea Therapeutics, to develop its promising candidate for idiopathic pulmonary fibrosis (IPF) and other fibrotic and inflammatory lung conditions.
Bayer has teamed up with Kumquat…
Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to a KRAS G12D inhibitor that is on the cusp of the clinic.
A day after posting a pair of…
A day after posting a pair of phase 3 wins for the tricky indication of Sjögren's syndrome, the Swiss pharma has unveiled a separate late-stage victory in another B-cell-driven autoimmune disease.
Vaxart is actively seeking more…
Vaxart is actively seeking more information about why it was told to stop work under a federally funded COVID-19 vaccine contract.
Another Massachusetts biotech has…
Another Massachusetts biotech has reached the end of the road. NextRNA Therapeutics has begun winding down operations with a “heavy heart,” the company’s co-founder, president and CEO Dominique Verhelle, Ph.D., announced in an Aug. 9
Young inflammatory disease biotech…
Young inflammatory disease biotech Expedition Therapeutics is paying $17 million cash for licensing rights to an investigational DPP-1 inhibitor from Fosun Pharma.
IO Biotech’s cancer vaccine has…
IO Biotech’s cancer vaccine has “narrowly” failed to beat Keytruda in a phase 3 melanoma trial, but the company remains hopeful of a path to approval.
Novartis may have abandoned one of…
Novartis may have abandoned one of its Sjögren's syndrome assets this year, but it now looks like the pharma has a winner on its hands.
The FDA has denied Stealth…
The FDA has denied Stealth BioTherapeutics’ request to reconsider its complete response letter, leaving the fate of the biotech and its investigational treatment for an ultrarare genetic disease hanging in limbo.
After the recent approval and…
After the recent approval and launch of twice-yearly HIV prophylactic Yeztugo, Gilead is cleaning up its R&D pipeline. The Bay Area company has dropped two early-stage cancer candidates and a Novo Nordisk-partnered combination treatment for
Bicycle Therapeutics is reducing…
Bicycle Therapeutics is reducing its headcount by around 25% to extend its cash runway into 2028. The layoffs, which are part of a push to cut spending by 30%, follow Genentech’s termination of an oncology
Ipsen has backed out of a $900…
Ipsen has backed out of a $900 million biobucks deal for Sutro Biopharma’s ROR1-directed antibody-drug conjugate.
Longevity company Altos Labs has…
Longevity company Altos Labs has secured a new clinical leader from the eye of the storm. Former Tornado Therapeutics co-founder and CEO Joan Mannick, Ph.D., is now senior vice president, chief medical officer and head
An impressive array of Big Pharma…
An impressive array of Big Pharma backers lined up to help ensure Strand Therapeutics has the funding needed to take its mRNA-based solid tumor drug further into the clinic.
Eli Lilly is pivoting its pain…
Eli Lilly is pivoting its pain pipeline, punting a midstage program it licensed from Centrexion Therapeutics while adding a candidate from its recent SiteOne Therapeutics buyout to its early-phase portfolio.
Minghui has secured $131 million…
Minghui has secured $131 million for what the company describes as a “pre-IPO” round to fuel the potential launch of its eye drug in China as well as various clinical-stage oncology and immunology assets.
Gilead has returned the rights to…
Gilead has returned the rights to a cancer candidate it licensed from Arcus Biosciences in a $725 million, multiprogram deal, confirming its retreat from an asset that was deprioritized earlier this year.
Keros has shaken up its leadership…
Keros has shaken up its leadership structure as the biotech attempts to shake off the failure of its blood pressure drug by going all in on an early-stage Duchenne muscular dystrophy asset.
As other pharmas drop next-gen…
As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to an average of 27.3 pounds in the first of two pivotal trials, queuing up plans for a